Michael Hufford
Dr. Hufford is the Chief Medical Officer and a co-founder of e-Nicotine Technology. He has 16 years of experience in nicotine research, drug development, and entrepreneurship. Dr. Hufford’s drug development experience includes serving as Vice President of Corporate and Clinical Development at Cypress Bioscience, where his responsibilities included. drug and medical device development in support of multiple CNS assets, including the clinical development and FDA approval of Savella® (milnacipran) for fibromyalgia. Dr. Hufford earned his Bachelor’s Degree with Distinction in Psychology from Purdue University, and his Master’s and Doctoral degrees in Clinical Psychology from the University of Pittsburgh, where his research focused on smoking and other addictive behaviors. He completed his clinical internship at the McLean Hospital, where he was a Clinical and Research Fellow in the Department of Psychiatry at Harvard Medical School.
As a professor at the University of Montana, he was an award-winning undergraduate lecturer and was the Principal Investigator for an addictive behaviors research lab focused on understanding proximal determinants of relapse across a variety of substance use disorders. He has more than 100 peer-reviewed publications, presentations and patents.
As a professor at the University of Montana, he was an award-winning undergraduate lecturer and was the Principal Investigator for an addictive behaviors research lab focused on understanding proximal determinants of relapse across a variety of substance use disorders. He has more than 100 peer-reviewed publications, presentations and patents.
Country:
USA